Tandem Diabetes Care Rides Record Quarter, Reaffirms Outlook

Tandem Diabetes Care ((TNDM)) has held its Q1 earnings call. Read on for the main highlights of the call.

Tandem Diabetes Care’s latest earnings call struck an upbeat tone, as management highlighted record pump shipments, robust revenue growth and expanding margins alongside solid cash generation and a fortified balance sheet. While acknowledging temporary pressures from infusion set shortages, early pharmacy transition friction and international timing quirks, executives emphasized that these headwinds are manageable against a clear product roadmap and reaffirmed guidance.

Record Shipments and Sales Momentum

Tandem delivered a first‑quarter record with more than 29,000 insulin pump shipments worldwide, translating into $247 million in sales and underscoring strong demand for its technology. U.S. shipments exceeded 19,000 units, up about 10% year over year, with domestic sales rising 7% to $161 million as renewals surpassed half of shipments and most new starts came from multiple daily injection users.

Margin Expansion and Profitability Progress

Profitability trends moved sharply in the right direction, with gross margin improving to 55%, nearly five percentage points higher than a year ago and the best first‑quarter level in company history. Adjusted EBITDA reached about 1% of sales, aided by a large swing from prior‑year R&D accounting, while operating margin improved by roughly 40 points to negative 7%, showing a narrowing path toward breakeven.

Strengthened Cash Position and Financing

The company generated $5 million in free cash flow during the quarter and finished with $570 million in total cash and investments, giving it ample flexibility to fund growth initiatives. Tandem also completed a convertible debt offering in February, raising $276 million of net proceeds at a zero percent coupon, which further buttressed its balance sheet without adding interest expense.

Early Progress on Pharmacy PayGo Transition

Management reported steady early traction for its PayGo model in the pharmacy channel, launched in March, with about 40% formulary coverage already in place and pharmacy representing roughly 6% of U.S. sales. While still small in absolute terms, leadership reiterated confidence that PayGo will ultimately enhance economics and scale efficiently as more patients and prescribers adapt to the new workflow.

International Direct-to-Customer Expansion

Tandem advanced its international shift toward direct commercial operations, launching its own sales infrastructure in the U.K., Switzerland and Austria to get closer to customers and capture more value. International pump shipments topped 10,000 units, driving $86 million in revenue and 3% growth, while direct channel sales rose to about 11% of international revenue from less than 5% historically.

Key Product and Technology Milestones

The quarter brought a series of product milestones, including extending Tandem Mobi access to U.S. Android users and securing regulatory clearance for Control‑IQ+ use in pregnant women, a first in automated insulin delivery. Integration with Abbott’s FreeStyle Libre 3+ is set to begin in select European markets in the second quarter, updates for Dexcom G7 compatibility are planned and Mobi’s commercial rollout outside the U.S. will also start in the same timeframe.

Pipeline Advancement: Mobi Tubeless and Closed-Loop

On the development front, Tandem is preparing a 510(k) submission in the second quarter for Mobi Tubeless, its first tubeless pump featuring extended‑wear technology and aimed at expanding its addressable market. The company also remains on track to initiate a pivotal study later this year for its fully closed‑loop system, which could further differentiate its automated insulin delivery portfolio over the medium term.

Infusion Set Supplier Shortages

A key infusion set supplier has faced capacity constraints since late last year, creating modest but material disruptions for certain customers and applying slight pressure on infusion set sales. Management expects these supply issues to persist for another quarter or two before easing in the second half, framing the impact as manageable within its broader growth outlook.

Operational Headwinds from Early PayGo Rollout

The launch of PayGo also brought near‑term friction, contributing roughly a $1 million headwind in the quarter as workflows around prescribing, fulfillment and physician outreach evolved. In the first weeks, fewer than 5% of customers ordered pumps through the pharmacy channel and supply orders via pharmacy represented less than 5% of the installed base, underscoring the early stage of the transition.

International Timing and One-Time Effects

Reported international results were influenced by several timing and one‑off factors, including a favorable currency environment and a one‑time Swiss accounting benefit that lifted first‑quarter sales. At the same time, expected headwinds from going direct, estimated at $3 million to $4 million, have shifted into the second quarter, and comparisons to 2025 will be complicated by a prior‑year distributor timing benefit of around $5 million.

Seasonal New-Starts and Early Sequential Softness

New pump starts dipped slightly both year over year and sequentially in the first quarter, a pattern the company attributed largely to normal seasonality that has historically weighed on early‑year activity. Management expressed confidence that new product introductions and increasing pharmacy penetration will reverse this softness later in the year and support renewed momentum in patient starts.

Pharmacy Conversion Friction for Existing Users

Transitioning existing durable medical equipment users to the pharmacy model has been slower than ideal, as it requires new prescriptions and additional engagement with physicians, adding administrative friction. Despite potential lower out‑of‑pocket costs for many patients, this extra complexity is moderating the initial pace of supply conversion, though the company views it as a temporary adjustment period.

Uncertain Timing for New Product Commercialization

While Tandem plans to file Mobi Tubeless for clearance in the second quarter with the possibility of approval in the back half of the year, management cautioned that the exact timing remains uncertain and is not embedded in meaningful 2026 revenue expectations. Any commercialization will be phased intentionally to avoid disruption to existing operations, emphasizing controlled execution over rapid rollout.

Forward Guidance and Outlook

The company reaffirmed its 2026 outlook, projecting worldwide sales of $1.065 billion to $1.085 billion, with U.S. revenue of $730 million to $745 million and international sales of $335 million to $340 million, supported by Q2 sales guidance around $255 million. Tandem also expects full‑year gross margins in the 56% to 57% range and adjusted EBITDA of 5% to 6%, assuming continued growth in pump shipments, modest infusion‑set constraints and gradual scaling of the pharmacy and direct channels.

Tandem Diabetes Care’s call painted a picture of a company accelerating on multiple fronts, balancing record operational metrics and improving margins with strategic investments in its pipeline and go‑to‑market model. While supply constraints, channel transitions and timing noise will likely cause some near‑term bumps, management’s reaffirmed guidance, robust cash position and visible innovation roadmap suggest investors may view these as growing pains rather than structural setbacks.